A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome

Trial Profile

A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Therapeutic Use
  • Sponsors Catalyst Pharmaceutical
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 03 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
    • 30 Aug 2017 According to a Catalyst Pharmaceuticals media release, expects to complete enrollment shortly and to announce top-line results in the fourth quarter of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top